Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its biosimilar version of Novo Nordisk’s Victoza (liraglutide), a treatment designed to control blood sugar levels in patients with type 2 diabetes (T2D).
Liraglutide, a human glucagon-like peptide 1 (GLP-1) analog, exhibits a 97% sequence homology with human GLP-1 and is primarily indicated for improving glycemic control in adults with T2D. Sino Biopharmaceutical’s biosimilar is the latest addition to the market, following Huadong Medicine’s biosimilar version, which was the first to gain approval in China ahead of the originator drug by Novo Nordisk, and the one manufactured by Tonghua Dongbao.- Flcube.com
